Filtered By:
Infectious Disease: Influenza

This page shows you your search results in order of date. This is page number 13.

Order by Relevance | Date

Total 693 results found since Jan 2013.

The impact of COVID-19 on patients with asthma
Conclusion Patients with asthma and COVID-19 were older and at increased risk due to comorbidity-related factors. ICS and biologics are generally safe and may be associated with a protective effect against severe COVID-19 infection.
Source: European Respiratory Journal - March 4, 2021 Category: Respiratory Medicine Authors: Izquierdo, J. L., Almonacid, C., Gonzalez, Y., Del Rio-Bermudez, C., Ancochea, J., Cardenas, R., Lumbreras, S., Soriano, J. B. Tags: Respiratory infections and tuberculosis Original Articles: Pulmonary infections Source Type: research

Study unravels antibiotic resistance in MRSA ‘superbug’ infections
FINDINGSResearchers applied a new approach pioneered at UCLA to predict whichmethicillin-resistant Staphylococcus aureus, or MRSA,infections willfail to respond toantibiotic treatment. By focusing on epigenetics — changes to gene expression that can’t be detected by standard DNA sequencing — the study examined how the immune system recognizes dangerous superbugs and works with antibiotics to clear them.BACKGROUNDThe Staphylococcus aureus bacterium can  live harmlessly on a person’s skin and in their nose, occasionally causing mild infections that can be treated with standard antibiotics. When itentersthe bloodstre...
Source: UCLA Newsroom: Health Sciences - March 3, 2021 Category: Universities & Medical Training Source Type: news

Johnson & Johnson Announces U.S. CDC Advisory Committee Recommends First Single-Shot COVID-19 Vaccine for Adults 18 and Older in U.S.
NEW BRUNSWICK, N.J., February 28, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, for individuals 18 years of age and older under the Emergency Use Authorization (EUA) issued by the U.S. Food and Drug Administration (FDA). “For more than 130 years, Johnson & Johnson has come to the aid of people during times of crisis, and we believe today’s re...
Source: Johnson and Johnson - February 28, 2021 Category: Pharmaceuticals Source Type: news

Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use
NEW BRUNSWICK, N.J., February 27, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. This decision was based on the totality of scientific evidence, including data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease across all regions studied, and showed protection against ...
Source: Johnson and Johnson - February 28, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Single-Shot COVID-19 Vaccine Candidate Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee
NEW BRUNSWICK, N.J., February 26, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted to recommend Emergency Use Authorization (EUA) for the Company’s single-shot COVID-19 vaccine candidate for adults 18 and older, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. The vote was based on a totality of scientific evidence provided by the Company, including efficacy and safety data from the Phase 3 ENSEMBLE trial. “We are extremely gratefu...
Source: Johnson and Johnson - February 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Announces Submission of Application to the U.S. FDA for Emergency Use Authorization of its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J., February 4, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that Janssen Biotech, Inc., has submitted an application to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for its investigational single-dose Janssen COVID-19 vaccine candidate. The Company’s EUA submission is based on topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose vaccine met all primary and key secondary endpoints. The Company expects to have product available to ship immediately following autho...
Source: Johnson and Johnson - February 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

We May Never Eliminate COVID-19. But We Can Learn to Live With It
When does a pandemic end? Is it when life regains a semblance of normality? Is it when the world reaches herd immunity, the benchmark at which enough people are immune to an infectious disease to stop its widespread circulation? Or is it when the disease is defeated, the last patient cured and the pathogen retired to the history books? The last scenario, in the case of COVID-19, is likely a ways off, if it ever arrives. The virus has infected more than 100 million people worldwide and killed more than 2 million. New viral variants even more contagious than those that started the pandemic are spreading across the world. And...
Source: TIME: Health - February 4, 2021 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Cover Story COVID-19 feature Magazine Source Type: news

Intranasal influenza vaccine spurs strong immune response in Phase 1 study
(NIH/National Institute of Allergy and Infectious Diseases) An experimental single-dose, intranasal influenza vaccine was safe and produced a durable immune response when tested in a Phase 1 study published in theJournal of Clinical Investigation. The investigational vaccine, called Ad4-H5-VTN, is a recombinant, replicating adenovirus vaccine designed to spur antibodies to hemagglutinin, a protein found on the surface of influenza viruses that attaches to human cells.
Source: EurekAlert! - Infectious and Emerging Diseases - February 3, 2021 Category: Infectious Diseases Source Type: news

Impact of Age and Region on Immune Responses to Allergy Immunotherapy
Allergy immunotherapy (AIT) can prevent allergic disease by modifying the adaptive immune system, similar to anti-pathogen vaccines, supporting the concept of AIT as an “allergy vaccination”. Some vaccines, e.g. influenza, pneumococcal pneumoniae, are administered globally with the same dose for all age groups. The aim of this study was to determine if sublingual immunotherapy (SLIT) across regions and age groups induce similar immunologic changes in IgE and Ig G4 with the goal of using the same dose and formulation worldwide.
Source: Journal of Allergy and Clinical Immunology - February 1, 2021 Category: Allergy & Immunology Authors: Josephine Nolte Peterlin, Vibeke Backer, Thomas Stranzl, Veronica Hulstroem, Peter Sejer Andersen, Hendrik Nolte Source Type: research

Improving Influenza Immunization Rates
Influenza virus is an important cause of respiratory disease during the winter months. This past flu season, our objective was to ensure =>80% of eligible patients seen in our clinic were up to date for the influenza vaccine by 1Dec2019.
Source: Journal of Allergy and Clinical Immunology - February 1, 2021 Category: Allergy & Immunology Authors: Jun Mendoza, James Quinn Source Type: research

Influenza Vaccination of High Risk Brooklyn Residents Questionnaire
To learn more about inner-city high-risk patients ’ knowledge and attitudes regarding influenza and influenza vaccine.
Source: Journal of Allergy and Clinical Immunology - February 1, 2021 Category: Allergy & Immunology Authors: Venkatesh Sabhae Gangadharappa, Rauno Joks Source Type: research

A Quality Improvement Initiative to Improve Resident- Physician Practices Regarding Flu Vaccine Administration in Individuals with Egg Allergy
Individuals with any severity of egg allergy, including anaphylaxis, should receive the influenza vaccine annually per CDC guidelines. This recommendation has evolved over the past ten years. We performed a quality improvement initiative to assess and improve resident physician practices regarding flu vaccine administration in egg allergic individuals.
Source: Journal of Allergy and Clinical Immunology - February 1, 2021 Category: Allergy & Immunology Authors: Aishwarya Navalpakam, Shweta Saini, Chi- Lan Tran, Jenny Huang, Divya Seth, Pavadee Poowuttikul Source Type: research

Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
NEW BRUNSWICK, N.J., January 29, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19. The Phase 3 ENSEMBLE study is designed to evaluate the efficacy and safety of the Janssen COVID-19 vaccine candidate in protecting moderate to severe COVID-...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Moderna ’s COVID-19 Vaccine Works Against the New Mutant Strains. Is That Enough?
First, the good news: in a study published Jan. 25 on a preprint server, Moderna says its COVID-19 vaccine continues to protect against two of the major mutant strains of SARS-CoV-2 circulating around the world: one that was first identified in the U.K. (called B.1.1.7) and one first seen in South Africa (B.1.351). Now, the not-so-good news. Blood from people vaccinated with the company’s shot did not generate as many immune antibodies against B.1.351 as they did against the non-mutant virus—in fact, this blood contained about six-fold lower levels of antibodies. However, in the study released on biorxiv by sci...
Source: TIME: Health - January 26, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news